Cipla’s manufacturing facility in Goa gets VAI classification

hanuman

Active member
us-fda-approval-1.jpg


Cipla’s manufacturing facility located in Goa receives a Voluntary Action Indicated (VAI) classification. This decision came after the United States Food and Drug Administration (US FDA) completed a Good Manufacturing Practices (cGMP) inspection conducted between June 10-21, 2024.

The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock